Ankylosing Spondylitis Market To Reach $9.12 Billion By 2030

Ankylosing Spondylitis Market Growth & Trends

The global ankylosing spondylitis market size is expected to reach USD 9.12 billion by 2030, registering a CAGR of 6.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province’s public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

 Request a free sample copy or view report summary: Ankylosing Spondylitis Market Report

Ankylosing Spondylitis Market Report Highlights

• The TNF (Tumor Necrosis Factor) segment dominated the market and accounted for a revenue share of 59.4% in 2023. TNF inhibitors, which target tumor necrosis factors to manage autoimmune conditions such as rheumatoid arthritis, are anticipated to experience significant growth.

• The Non-steroidal Anti-Inflammatory Drug (NSAID) market is expected to grow at a CAGR of 8.8% over the forecast years.

• The North America ankylosing spondylitis market accounted for the largest revenue share of 57.9% in 2023

• Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share

• For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China

Ankylosing Spondylitis Market Segmentation

Grand View Research has segmented the global ankylosing spondylitis market on the basis of on drug class, distribution channel, and region:

Ankylosing Spondylitis Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Non-Steroidal Anti Inflammatory Drug(NSAID)

• TNF Inhibitors

  • • Humira

    • Simponi

    • Remicade

    • Enbrel

    • Cimzia

    • Other TNF Inhibitors

• Other Drug Classes

Ankylosing Spondylitis Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Others

Ankylosing Spondylitis Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • South Africa

  • Kuwait

List of Key Players in the Ankylosing Spondylitis Market

• AbbiVie, Inc.

• Amgen, Inc.

• Pfizer, Inc.

• Johnson & Johnson, Inc.

• Novartis AG

• UCB, Inc.

• Eli Lilly and Company

• Merck & Co., Inc.

• Zydus Lifescience ltd.

• Izana Bioscience